Wound dressing with vacuum reservoir

Information

  • Patent Grant
  • 11896754
  • Patent Number
    11,896,754
  • Date Filed
    Wednesday, October 30, 2019
    4 years ago
  • Date Issued
    Tuesday, February 13, 2024
    2 months ago
Abstract
A wound dressing apparatus includes a wound dressing member dimensioned for positioning relative to a wound bed. The wound dressing member including an internal vacuum reservoir and has a port in communication with the vacuum reservoir for applying subatmospheric pressure to the vacuum reservoir to facilitate removal of fluid from the wound bed. The wound dressing member includes a visual pressure indicator associated therewith for indicating a level of pressure within the vacuum reservoir. The visual pressure indicator includes color indicia having a plurality of colors corresponding to a condition of the pressure within the vacuum reservoir. The wound dressing member includes a lower absorbent member positionable adjacent the wound bed and an upper member which at least partially defines the vacuum reservoir. At least one of the top member and the lower absorbent member has the visual pressure indicator mounted thereto.
Description
BACKGROUND
1. Technical Field

The present disclosure relates to an apparatus for treating an open wound, and, more specifically, relates to a wound dressing that draws wound fluids into a vacuum reservoir to facilitate the wound healing process.


2. Description of Related Art

Wound closure involves the migration of epithelial and subcutaneous tissue adjacent the wound towards the center of the wound until the wound closes. Unfortunately, closure is difficult with large wounds or wounds that have become infected. In such wounds, a zone of stasis (i.e. an area in which localized swelling of tissue restricts the flow of blood to the tissues) forms near the surface of the wound. Without sufficient blood flow, the epithelial and subcutaneous tissues surrounding the wound not only receive diminished oxygen and nutrients, but, are also less able to successfully fight microbial infection and, thus, are less able to close the wound naturally. Such wounds have presented difficulties to medical personnel for many years.


Wound dressings have been used in the medical industry to protect and/or facilitate healing of open wounds. One popular technique has been to use negative pressure therapy, which is also known as suction or vacuum therapy. A variety of negative pressure devices have been developed to allow excess wound fluids, i.e., exudates to be removed while at the same time isolating the wound to protect the wound and, consequently, reduce recovery time. Various wound dressings have been modified to promote the healing of open wounds.


Issues that continually need to be addressed when using a wound dressing include ease of use, efficiency of healing a wound, and the source of constant or varying negative pressure. Thus, there remains a need to constantly improve negative pressure wound dressings for open wounds.


SUMMARY

In one preferred embodiment, a wound dressing apparatus includes a wound dressing member dimensioned for positioning relative to a wound bed. The wound dressing member includes an internal vacuum reservoir and having a port in communication with the vacuum reservoir for applying subatmospheric pressure to the vacuum reservoir to facilitate removal of fluid from the wound bed. The wound dressing member includes an access door associated therewith and being selectively movable between a closed position substantially enclosing the vacuum reservoir and an open position permitting access to the vacuum reservoir.


The wound dressing member preferably includes a lower absorbent member which is positionable adjacent the wound bed and an upper member. The upper member at least partially defines the vacuum reservoir. The access door is mounted to the upper member. The lower member may comprise a material selected from the group consisting of foams, nonwoven composite fabrics, cellulosic fabrics, super absorbent polymers, hydrogels and combinations thereof. The lower member also may include at least one of a medicament, an anti-infective agent, an antimicrobial, such as polyhexamethylene biguanide (hereinafter, “PHMB”), antibiotics, analgesics, healing factors, vitamins, growth factors, debridement agents and nutrients. The wound dressing member may include an adhesive member which is adapted to be secured about the wound bed to provide a seal between the wound dressing member and tissue surrounding the wound bed.


The wound dressing apparatus may further include a vacuum source in fluid communication with the port. The vacuum source is adapted to supply subatmospheric pressure in a range between about 20 mmHg and about 500 mmHg to the vacuum reservoir. The port may include valve means.


The wound dressing member may include a visual pressure indicator for indicating a level of pressure within the vacuum reservoir. The preferred visual pressure indicator includes color indicia which correspond to a condition of the subatmospheric pressure within the vacuum reservoir. The preferred visual pressure indicator includes a position sensor. The visual pressure indicator may include circuit means and visible alarm means. The circuit means is adapted to actuate the visible alarm means when the position sensor detects a relative positioning of the top member of the wound dressing member to provide a visual indication of the condition of the subatmospheric pressure within the vacuum reservoir.


In another embodiment, a wound dressing apparatus includes a wound dressing member dimensioned for positioning relative to a wound bed. The wound dressing member including an internal vacuum reservoir and has a port in communication with the vacuum reservoir for applying subatmospheric pressure to the vacuum reservoir to facilitate removal of fluid from the wound bed and stimulate wound healing. The wound dressing member includes a visual pressure indicator associated therewith for indicating a level of pressure within the vacuum reservoir. The visual pressure indicator may include color indicia having a plurality of colors corresponding to a condition of the pressure within the vacuum reservoir. The wound dressing member includes a lower absorbent member positionable adjacent the wound bed and an upper member which at least partially defines the vacuum reservoir. At least one of the top member and the lower absorbent member has the visual pressure indicator mounted thereto. The visual pressure indicator may include an electronic position sensor. The visual pressure indicator may further include circuit means and visible alarm means. The circuit means is adapted to actuate the visible alarm means when the position sensor detects a relative positioning of the top member of the wound dressing member to provide a visual indication of the condition of the subatmospheric pressure within the vacuum reservoir.





BRIEF DESCRIPTION OF THE DRAWINGS

Various embodiments of the subject wound dressing are described herein with reference to the drawings wherein:



FIG. 1 is a side cross-sectional view of the wound dressing apparatus in accordance with the principles of the present disclosure on a wound bed;



FIG. 2 is a view similar to the view of FIG. 1 illustrating the wound dressing subjected to subatmospheric pressure;



FIG. 3 is a top view of the wound dressing;



FIG. 4 is a view similar to the view of FIG. 2 illustrating the access door in an open condition to permit access to the internal vacuum reservoir;



FIG. 5 is a cross-sectional view taken along the lines 5-5 of FIG. 3 illustrating the visual pressure indicator;



FIG. 6 is a block diagram illustrating the components of the electronic visual indicator device;



FIG. 7 is a view similar to the view of FIG. 1 illustrating an alternate embodiment of the present disclosure;



FIG. 8 is a view illustrating an alternate visual indicia arrangement of the visual indicator device;



FIG. 9 is a side cross-sectional view of an alternate wound dressing on a wound bed and in the absence of a vacuum;



FIG. 10 is a view similar to the view of FIG. 9 illustrating the wound dressing in a contracted condition when subjected to subatmospheric pressure; and



FIG. 11 is a top view of the wound dressing of FIG. 9.





DESCRIPTION OF THE PREFERRED EMBODIMENTS

The composite wound dressing of the present disclosure promotes healing of a wound via the use of a vacuum reservoir. The vacuum reservoir subjects the wound to vacuum or subatmospheric pressure to effectively draw wound fluid including liquid exudates from the wound bed without the continuous use of a vacuum source or pump. Hence, vacuum pressure can be applied once or in varying intervals depending on the nature and severity of the wound until the composite wound dressing is saturated with exudate or the wound is healed. If the wound dressing is saturated with exudate and the wound is not healed, certain and/or all layers of the composite wound dressing can be replaced and the process of applying subatmospheric pressure can be repeated.


Referring now to FIGS. 1-3, the composite wound dressing 100 in accordance with a preferred embodiment of the present disclosure is illustrated in the form of an article with multiple layers arranged in juxtaposed or superposed relation. The multiple layers include, but, are not limited to a lower or base layer 102, an absorbent/packing layer 104, an adherent layer 106, and a top layer 108 which includes and/or defines the internal vacuum reservoir 110.


The base layer 102 is in direct contact with the wound bed “w”. The base layer 102 is typically porous allowing passage of subatmospheric pressure to the wound bed. In one preferred embodiment, the base layer includes a “non-adherent” material. “Non-adherent” as used herein refers to a material that does not adhere to tissues in and around the wound bed. “Porous” as used herein refers to a material which contains numerous small perforations or pores which allow wound fluids of all kinds to pass through the material to the dressing layers above. The passage of wound fluid through the porous material may be unidirectional such that wound exudate does not flow back to the wound bed. This direction flow feature could be in the form of directional apertures imparted into the material layer, a lamination of materials of different absorption to the base layer 102 or specific material selection that encourages directional flow. Exemplary materials used as the base layer 102 include a contact layer sold under the trademark XEROFLOW® by Kendall Corp., a division of TycoHealthcare. In the alternative, the base layer 102 may include an adherent material.


In addition, agents such as hydrogels and medicaments could be bonded or coated to the base layer 102 to reduce bioburden in the wound, promote healing and reduce pain associated with dressing changes or removal. Medicaments include, for example, antimicrobial agents, growth factors, antibiotics, analgesics, debridement agents and the like. Furthermore, when an analgesic is used, the analgesic could include a mechanism that would allow the release of that agent prior to dressing removal or change. Exemplary triggers of a release mechanism could be temperature change.


The layer proximal to the base layer 102 or composite structures making the base layer 102 is the absorbent/packing layer 104. The absorbent/packing layer 104 of the wound dressing 100 is intended to absorb and capture wound fluid and exudates. Exemplary absorbent materials include foams, nonwoven composite fabrics, hydrogels, cellulosic fabrics, super absorbent polymers, and combinations thereof. Typically, the absorbent/packing layer 104 can absorb up to about 100 cubic centimeters (cc) or more of wound fluid. Preferably, the absorbent material includes the antimicrobial dressing sold under the trademark KERLIX® by Kendall Corp., a division of TycoHealthcare. In one preferred embodiment, the absorbent/packing layer 104 could be preformed or shaped to conform to varying shapes of the wound bed. Those skilled in the art will recognize that the absorbent/packing layer 104 can be formed in any suitable shape. Absorbent/packing layer 104 may include multiple layers. The only requirement as to shape is that the absorbent/packing layer 104 is suitable to treat a particular shape of the wound.


Additionally, the absorbent/packing layer 104 could be treated with medicaments. Medicaments include, for example, an anti-infective agent such as an antiseptic or other suitable antimicrobial or combination of antimicrobials, polyhexamethylene biguanide (hereinafter, “PHMB”), antibiotics, analgesics, healing factors such as vitamins, growth factors, nutrients and the like, as well as a flushing agent such as isotonic saline solution.


With continued reference to FIGS. 1-3, the adherent layer 106 at least encompasses the perimeter of the wound dressing 100 to surround the wound bed to provide a seal around the perimeter of the wound bed “w”. For instance, the sealing mechanism may be any adhesive bonded to a layer that surrounds the wound bed “w” or an adhesive applied directly to the skin. The adhesive must provide acceptable adhesion to the tissue “t” surrounding the wound bed “w” skin, e.g., the periwound area, and be acceptable for use on skin without contact deterioration (for example, the adhesive should preferably be non-irritating and non-sensitizing.) The adhesive may be semi-permeable to permit the contacted skin to transmit moisture or may be impermeable. Additionally, the adhesive could be activated or de-activated by an external stimulus such as heat or a given fluid solution or chemical reaction. Adhesives include, for example, the dressing sold under the trademark ULTEC® Hydrocolloid dressing by Kendall Corp., a division of TycoHealthcare.


The adherent layer 106 may also be in the form of an entire layer proximal to the absorbent/packing layer 104 or preferably is annular or “donut shaped” as shown. Preferably, the adherent layer 106 is not bonded to the absorbent/packing layer 104 to allow for easy replacement of the absorbent/packing layer 104. In a preferred embodiment, the adherent layer 106 is at least bonded to the periphery of the base layer 102. In turn, the peripheral portion 108a of the top layer 108 may be bonded to the adherent layer 106 to provide a seal around the perimeter of the wound. Alternatively, the adherent layer 106 may be positioned on the peripheral portion 108a of the top layer 108 and secured to the tissue “t” about the wound bed “w”, and not bonded to the base layer 102. As a further alternative, the peripheral portion 108a of the top layer 108 may include an adhesive surface. It is anticipated that removable contact liners may also be used to protect the adhesive surface of the adherent layer 106 prior to use.


The top or upper layer 108 typically seals the top of the wound dressing 100 and helps maintain the appropriate vacuum level within the wound dressing 100. In one preferred embodiment, the top layer 108 includes the flexible transparent dressing manufactured under the trademark POLYSKIN® II by Kendall Corp., a division of TycoHealthcare. POLYSKIN® II is a transparent, semi-permeable material which permits moisture and oxygen exchange with the wound site, and provides a barrier to microbes and fluid containment. In the alternative, the top layer 110 may be impermeable. As a further alternative, the top layer 108 may include a resilient, e.g., elastomeric, material in the shape, e.g., of a dome.


The top layer 108 defines a sealed or enclosed vacuum reservoir 110. The vacuum reservoir 110 is preferably maintained at an appropriate vacuum level for a predetermined period of time sufficient to initiate or complete healing of the wound bed “w”, i.e., to draw wound fluid and exudate away from the wound bed “w” while subjecting the wound to subatmospheric pressure. The vacuum may be re-applied as needed to maintain a therapeutic effect. The vacuum may be continuous or intermittent as desired.


As best seen in FIG. 1, the vacuum reservoir 110 is defined within the dome of the top layer 108. As shown in FIG. 2, once vacuum is applied, the dome of the top layer 108 is drawn downwardly toward the absorbent/packing layer 104 with the vacuum or subatmospheric reservoir 110 created beneath the top layer 108. Typically, the top layer 108 includes a vacuum port or connector 114 in fluid communication with the vacuum reservoir 110. Preferably, the vacuum port 114 includes a one-way valve (shown schematically as reference numeral 116) which provides unidirectional flow of suction and may provide a means for allowing connection of the composite wound dressing 100 to the vacuum source 112. The one way valve 116 may be incorporated within the vacuum port 114 or, alternatively, be “in line” with the vacuum source 112. A flexible tubing 118 is connected to the vacuum port 114 and the vacuum source 112. The tubing 118 provides suction to the wound from the vacuum source 112 and enables the wound fluid to be transferred from the wound dressing 100. The tubing 118 may be fabricated from PVC, silicone based material or other flexible materials (polymers). The tubing 118 may optionally include a connection to a collection canister 120 for wound drainage and debris. Hence, the vacuum source 112 can draw wound fluid through the composite wound dressing 100 and tubing 118 into the canister 120. In a preferred embodiment of the present disclosure, the canister 120 is portable so that the patient will have the freedom to move about rather than being confined to a fixed location. The canister 120 may also house an absorbent material to absorb wound fluid and exudate.


The vacuum source 112 may apply vacuum to the wound by means such as a manual pump as disclosed in commonly assigned U.S. Pat. No. 5,549,584 to Gross, the entire contents of which are hereby incorporated herein by reference. In the alternative, the vacuum source 112 may include an automated pump. Typically, the vacuum level is in a range between about 20 mmHg to about 500 mmHg, more preferably, about 40 mmHg and about 125 mmHg. The automated pump may be a wall suction apparatus such as those available in an acute or sub-acute care facility. The automated pump may be in the form of a portable pump. The portable pump may include a small or miniature pump that maintains or draws adequate and therapeutic vacuum levels. In a preferred embodiment, the pump is a portable, lightweight, battery operated, suction pump which attaches to the distal end of the tubing. Typically, the vacuum source 112 has regulation means to apply the optimal vacuum pressure for healing the wound. Furthermore, the vacuum source 112 would preferably contain a mechanism to detect a leak in the system if the optimal vacuum pressure is not achieved. Preferably, the vacuum source 112 would also contain an indicator (not shown) to indicate when the optimal vacuum pressure is achieved. In the alternative, a hand pump in the form of a squeeze bulb or a foot pump may serve as the vacuum source 112.


Preferably, a pump is used as the vacuum source 112. Typical pumps include diaphragm or voice coil activated styles that can deliver variable vacuum up to 50 cc/minute.


With reference now to FIGS. 1-4, the top layer 108 may include an access door 122 to provide access to the interior of the wound dressing 100 and/or the wound bed “w”. The door 122 could be a flap integrally formed with the top layer 108 or a separate component connected to the top layer 108 via a hinge or the like. The door 122 is preferably resealable to maintain the integrity of the vacuum reservoir 110 and provide a seal relative to the top layer 108. One suitable means for releasably sealing the door 122 includes a snap fit arrangement, tongue and groove arrangement, “Zip Lock®” arrangement, adhesives, VELCRO®, etc. The door 122 preferably provides access to the wound bed “w” to enable the clinician to monitor the status of the wound, change the absorbent/packing layer 104, or apply additional medical treatment to the wound such as antimicrobial agents, growth factors, debriders, or other wound healing agents as needed. Once the desired procedure is completed, the door 122 would be resealed relative to the top layer 108 to maintain the integrity of the vacuum reservoir 110. FIG. 4 illustrates the removal of the absorbent/packing layer 104 through the door 122 when the door 122 is in an open position. As discussed, a new absorbent/packing layer 104 subsequently may be introduced through the door 122 to absorb the exudates from the wound bed “w”.


With reference now to FIGS. 3 and 5, in conjunction with FIGS. 1-2, the wound dressing 100 may include a visual indicator device 124 mounted to the top layer 108 to provide a visual indication of vacuum pressure within the wound dressing 100. The visual indicator device 124 may include at least one electronic position indicator for detecting the relative position of the top layer 108 and the wound bed, and, thus the state of the vacuum within the wound dressing 100. In accordance with this embodiment, the top layer 108 may have a resilient characteristic either through the material of construction of the top layer 108 or through reinforcement (e.g., elastomeric) members incorporated in the top layer 108.


In one embodiment depicted in FIG. 6, the visual indicator device 124 includes at least one, preferably, three position-sensitive switches 126a-126c, and a self-powered electronic signaling module 128. The module 128 may include an electronic signaling module circuit board 130, a battery power source 132, at least one transducer including three light emitting diodes (LED) 134a-c and/or a loudspeaker 136 electrically connected 138 to the circuit board 130. The LEDs 134a-c are color coded red, yellow and green respectively. The position-sensitive switches 126a-126c each may be a pressure sensor which electrically bridges contacts 140a, 140b of the visual indicator device 124.


In the embodiment shown, three position switches 126a-c are mounted to top layer 108. The switches 126a-c include switch plates or contact arms arranged as a series of decreasing diameter annular coaxial elements. Alternatively, the switches may be linear in configuration depending downwardly from the top layer 108. The switch plate or contact arm of switches 126a-c are of predetermined length extending downwardly from the top layer 108 within the vacuum reservoir 110. (FIGS. 4 and 5) The contact arm of outer switch 126a of the pressure indicator 124 has the greatest length. The contact arm of the middle switch 126b has a length less than the length of the contact arm of the outer ring 126a. The contact arm of the inner switch 126c has the smallest length. The contacts 140a of switches 126a-c are integrated within the contact arms. Contacts 140b of the switches 126a-c may be disposed on the top surface of the absorbent/packing layer 104 or integrated within the absorbent/packing layer 104 in general longitudinal alignment with their respective contact arms. Alternatively, the position sensor may be a magnetic proximity sensor. The self-powered electronic signaling module 130 may be any conventional modules adapted to emit light and/or audible sound etc. upon closing of the switch.


When the top layer 108 is drawn down by vacuum pressure within the vacuum reservoir 110 toward its vacuum state of FIG. 2, inner switch 126c is in contact with a respective coupler or contact 140b disposed within the absorbent/packing layer 104 thereby energizing the visual indicator device 124 to illuminate the green LED 134c within the pressure indicator device mounted to the top layer 108. The green light of the LEDs 134c indicates a full vacuum condition of the vacuum reservoir 110. As appreciated, switches 126a, 126b may also be in contact with their respective couplers in this vacuum condition of top layer 108. However, it is envisioned that circuit board 130 will incorporate circuitry to override the electrical contact of these two switches when switch 126c is in contact with its respective coupler.


As vacuum pressure decreases and the dome of the top layer 108 begins to assume its normal condition of FIG. 1, through, e.g., the resilient characteristic of the top layer 108 discussed hereinabove, the inner switch 126c loses contact with the absorbent/packing layer 104 while the middle switch 126b maintains/establishes electrical contact with its associated contact 140b. The electrical connection of the middle switch 126b results in illumination of the yellow LED 134b. The yellow LED 134b represents a partial vacuum or marginal vacuum condition of the vacuum reservoir 110. As the vacuum pressure further decreases and the top layer 108 moves towards its fully expanded or normal condition of FIG. 1, the outer switch 126a is the remaining switch in contact with its associated contact 140b within the absorbent/packing layer 104. In this condition, the red LED 134a is energized and visible to the clinician essentially providing a warning that the vacuum within the vacuum reservoir has dissipated or is nearly dissipated (i.e., subatmospheric pressure is close to or no longer present). Consequently, the vacuum source 112 may be actuated either manually or automatically to reestablish the vacuum state within the vacuum reservoir 110. Further vacuum loss will result in the remaining switch 126c losing its contact where no lights are visible to the patient.


It is also envisioned that the circuit board 130 could be devoid of the aforementioned override circuitry. As a result, in the full vacuum condition of dressing 100, each of the green, yellow and red LEDs 134a-134c would be illuminated while in the partial vacuum state, the yellow and red LEDs 134a, 134b would be illuminated and in the warning state, the red LED 134a would be illuminated. It is further envisioned that the loudspeaker 136 could emit an audible alarm when any of the aforementioned vacuum states are realized.



FIG. 7 illustrates an alternate embodiment of the visual pressure indicator 124. In accordance with this embodiment, the visual pressure indicator 124 is mounted to the absorbent/packing layer 104 or positioned on the absorbent/packing layer 104 in juxtaposed relation. The top layer 108 is preferably transparent to permit viewing of the pressure indicator 124 through the top layer 108 and into the vacuum reservoir 110. The positioning of the visual pressure indicator 124 is reversed or arranged on its back in a manner where the respective switches 126a-c extend upwardly toward top layer 108. The respective coupler or contacts 140b are incorporated within the top layer 108. In the full vacuum state or condition of FIG. 2, the contact 140b of the top layer 108 is in contact with the switch 126c thereby energizing the LED 134c to display the green color to the clinician. During healing, as the vacuum reservoir begins to lose its vacuum, the top layer 108 moves towards its open condition of FIG. 1, the inner switch 126c loses its contact with its respective coupler 140b of the top layer 108 resulting in electrical contact with the yellow LED 134b indicating a partial vacuum condition of the vacuum reservoir 110. Continued loss of vacuum within the vacuum reservoir 110 causes the electrical contact of the coupler 140b with the outer switch 126c. This contact of the LED 134c with the outer switch 126c is indicated by the presence of its red color and may correspond to a loss or near loss of vacuum within the vacuum reservoir 110 thus prompting the clinician to activate the vacuum source 112 or pursue other clinical measures.



FIG. 8 illustrates another embodiment where the LEDs 134a-134c are supplemented with additional visual indicia. The visual indicia may include various symbols which correspond to the state of the vacuum within the vacuum reservoir 110. When a desired level of vacuum is reached, the “smiley” symbol 152 would illuminate indicating an adequate vacuum state. A partial vacuum state would result in the illumination of the “caution triangle” symbol 154. A loss or near loss of vacuum would result in the illumination of the “octagon” symbol (no vacuum) 156. One skilled in the art will readily appreciate the design of electronic circuitry to achieve this objective.



FIGS. 9-11 illustrate an alternate embodiment of the present disclosure. In accordance with this embodiment, the visual indicator device 124 may include a series of rings 200,202,204 disposed on the underside of the top layer 108, e.g., printed on the top layer 108, and arranged in concentric relation as shown. The rings include outer ring 200, middle ring 202 and inner ring 204 and are color coded red, yellow and green, respectively. Each colored ring 200,202,204 is positioned to contact the absorbent/packing layer 104 depending on the state or condition of the vacuum within the vacuum reservoir 110. Under full vacuum depicted in FIG. 10, all the rings 200,202,204 would contact absorbent/packing layer 104 and thus be activated and visible through the top of the wound dressing. As the vacuum within the reservoir dissipates or is reduced, the top layer 110 pulls away from the absorbent/packing layer 104. In one embodiment with an elastomeric dome, the inner ring 204 first loses contact followed by the middle and outer rings, 202, 200, respectively, as the vacuum is reduced. As each colored ring 200,202,204 loses contact with absorbent/packing layer 104, the respective ring becomes less visible or not visible from above the wound dressing 100 thus indicating to the clinician the condition of the vacuum within the vacuum reservoir. The rings 200,202,204 may incorporate electronic switches to be activated in the manner discussed hereinabove in connection with the embodiment of FIGS. 1-6. Alternatively, each ring 200,202,204 may incorporate an analytical test strip device which, e.g., may detect the presence of a predetermined analyte in the exudates contained in the absorbent/packing layer 104. Upon contact with the predetermined analyte, the test strip device of each ring 200,202,204 assumes a color such as red, yellow or green. When a respective ring 200,202,204 loses contact with the predetermined analyte, the color of the respective ring may fade or assume a neutral color. One exampled of a color coded test strip device suitable for use with the present disclosure is disclosed in U.S. Pat. No. 7,049,130 to Carroll et al., issued May 23, 2006, the entire contents of which are incorporated herein by reference. One skilled in the art may determine the parameters and characteristics of a test strip device to perform the objectives discussed hereinabove.


In addition, the door 122 of the embodiment of FIGS. 9-11 is adapted to pivot along hinge 208 to provide access to the vacuum reservoir 110. The opening of the door 122 is disposed adjacent the periphery of the wound dressing 102 and thus provides a relatively large access opening upon pivoting or opening the door 122 along the hinge 208. This facilitates removal and replacement of absorbent/packing layer 104.


It is further contemplated that the wound dressing apparatus may incorporate external means or applications to stimulate tissue growth and/or healing. For example, an ultrasonic transducer may be incorporated into the wound dressing apparatus to impart mechanical energy for the treatment of the tissue such as, for instance, directing thermal or vibratory energy on the wound area to stimulate healing and/or further encouraging exudates removal by vacuum and/or introducing various drugs into the human body through the skin. Other sensor types are also contemplated for incorporation into the wound dressing apparatus including oxygen, chemical, microbial and/or temperature sensors. The detection of oxygen adjacent the wound area would assist the clinician in determining the status of wound healing. The presence of an elevated temperature may be indicative of an infection.


While the disclosure has been illustrated and described, it is not intended to be limited to the details shown, since various modifications and substitutions can be made without departing in any way from the spirit of the present disclosure. For example, it is envisioned the subject matter of the commonly assigned U.S. patent application Ser. No. 11/517,210, filed on Sep. 6, 2006, and which claims priority to U.S. Provisional Application Ser. No. 60/714,812, filed on Sep. 6, 2005, and the subject matter of the commonly assigned U.S. patent application Ser. No. 11/516,216, filed on Sep. 6, 2006, and which claims priority to provisional application No. 60/714,912, filed on Sep. 7, 2005, (the entire contents of each application being incorporated herein) may be incorporated into the present disclosure. As such, further modifications and equivalents of the invention herein disclosed can occur to persons skilled in the art using no more than routine experimentation, and all such modifications and equivalents are believed to be within the spirit and scope of the disclosure as defined by the following claims.

Claims
  • 1. A wound dressing apparatus for use in negative pressure wound therapy, comprising: a porous layer configured to be in direct contact with a wound;a wound cover layer dimensioned for positioning over the wound, wherein the wound cover layer defines an internal vacuum reservoir when the wound cover layer is positioned over the wound;a fabric layer positioned between the porous layer and the wound cover layer; anda visual indicator device in communication with the wound cover layer and configured to display a condition of the wound dressing apparatus, wherein the visual indicator device comprises a display comprising visual indicia and wherein the visual indicia comprises various symbols wherein each symbol correspond to a different condition of the wound dressing apparatus.
  • 2. The wound dressing apparatus of claim 1, further comprising a canister for collection of wound exudate.
  • 3. The wound dressing apparatus of claim 1, wherein the porous layer further comprises at least one medicament.
  • 4. The wound dressing apparatus of claim 1, further comprising a connector on the wound cover layer in fluid communication with the internal vacuum reservoir and configured to be connected with a source of negative pressure.
  • 5. The wound dressing apparatus of claim 4, wherein the connector extends into the internal vacuum reservoir.
  • 6. The wound dressing apparatus of claim 1, wherein the wound cover layer comprises an access door to provide access to an interior of the internal vacuum reservoir.
  • 7. The wound dressing apparatus of claim 1, wherein the visual indicator device is mounted to the wound cover layer.
  • 8. The wound dressing apparatus of claim 1, wherein the visual indicator device is configured to display a visual indication of vacuum pressure within the internal vacuum reservoir.
  • 9. The wound dressing apparatus of claim 8, wherein the visual indicator device comprises a plurality of pressure indicators configured to display different visual indications at different levels of vacuum pressure within the internal vacuum reservoir.
  • 10. The wound dressing apparatus of claim 1, wherein the visual indicia comprises various symbols which correspond to a state of a vacuum pressure within the internal vacuum reservoir.
  • 11. The wound dressing apparatus of claim 1, further comprising an adhesive material on an underside of the wound cover layer on a peripheral portion of the wound cover layer, the adhesive material configured to be secured to tissue surrounding the wound.
  • 12. The wound dressing apparatus of claim 11, further comprising a removable contact liner attached to the adhesive material and configured to be removed prior to use of the wound dressing apparatus.
  • 13. The wound dressing apparatus of claim 11, further comprising an adherent layer, wherein the adhesive material is on the adherent layer.
  • 14. A wound dressing apparatus, comprising: a porous layer configured to be in contact with a wound;a wound cover layer positioned over the porous layer;a fabric layer positioned between the porous layer and the wound cover layer; anda visual indicator device in communication with the wound cover layer and configured to display a condition of the wound dressing apparatus, wherein the visual indicator device comprises a display comprising visual indicia and wherein the visual indicia comprises various symbols wherein each symbol correspond to a different condition of the wound dressing apparatus.
  • 15. The wound dressing apparatus of claim 14, wherein the fabric layer is an absorbent member comprising a super absorbent material.
CROSS-REFERENCE TO RELATED APPLICATIONS

This patent application is a continuation application of U.S. patent application Ser. No. 15/280,009, filed on Sep. 29, 2016, which is a continuation application of U.S. patent application Ser. No. 14/585,589, filed on Dec. 30, 2014 and now U.S. Pat. No. 9,456,928, which is a continuation application of U.S. patent application Ser. No. 13/775,964, filed on Feb. 25, 2013 and now U.S. Pat. No. 8,956,336, which is a continuation application of U.S. patent application Ser. No. 12/686,813, filed on Jan. 13, 2010 and now U.S. Pat. No. 8,409,157, which is a divisional application of U.S. patent application Ser. No. 11/516,925, filed on Sep. 6, 2006 and now U.S. Pat. No. 7,699,823, which claims the benefit of U.S. Provisional Patent Application No. 60/714,805, filed on Sep. 7, 2005, the entire contents of each are incorporated herein by this reference.

US Referenced Citations (287)
Number Name Date Kind
3874387 Barbieri Apr 1975 A
3972328 Chen Aug 1976 A
4029598 Neisius et al. Jun 1977 A
4224941 Stivala Sep 1980 A
4366169 White Dec 1982 A
4398910 Blake et al. Aug 1983 A
4568327 Seufert Feb 1986 A
4581821 Cahalan et al. Apr 1986 A
4624656 Clark et al. Nov 1986 A
4655754 Richmond et al. Apr 1987 A
4681562 Beck et al. Jul 1987 A
4710165 McNeil et al. Dec 1987 A
4728499 Fehder Mar 1988 A
4813942 Alvarez Mar 1989 A
4826494 Richmond et al. May 1989 A
4969880 Zamierowski Nov 1990 A
5055195 Trasch et al. Oct 1991 A
5055198 Shettigar Oct 1991 A
5056510 Gilman Oct 1991 A
5100396 Zamierowski Mar 1992 A
5106629 Cartmell et al. Apr 1992 A
5141503 Sewell, Jr. Aug 1992 A
5152757 Eriksson Oct 1992 A
5176663 Svedman et al. Jan 1993 A
5181905 Flam Jan 1993 A
5234419 Bryant et al. Aug 1993 A
5238732 Krishnan Aug 1993 A
5261893 Zamierowski Nov 1993 A
5527293 Zamierowski Jun 1996 A
5549584 Gross Aug 1996 A
5562107 Lavender et al. Oct 1996 A
5636643 Argenta et al. Jun 1997 A
5643189 Masini Jul 1997 A
5645081 Argenta et al. Jul 1997 A
5678564 Lawrence et al. Oct 1997 A
5701917 Khouri Dec 1997 A
5707499 Joshi et al. Jan 1998 A
5759570 Arnold Jun 1998 A
5779657 Daneshvar Jul 1998 A
5833646 Masini Nov 1998 A
5852126 Barnard et al. Dec 1998 A
5902256 Benaron May 1999 A
5911222 Lawrence et al. Jun 1999 A
6071267 Zamierowski Jun 2000 A
6103275 Seitz et al. Aug 2000 A
6117111 Fleischmann Sep 2000 A
6135116 Vogel et al. Oct 2000 A
6142982 Hunt et al. Nov 2000 A
6168800 Dobos et al. Jan 2001 B1
6174306 Fleischmann Jan 2001 B1
6183438 Berguer Feb 2001 B1
6225523 Masini May 2001 B1
6261276 Reitsma Jul 2001 B1
6261283 Morgan et al. Jul 2001 B1
6345623 Heaton et al. Feb 2002 B1
6398767 Fleischmann Jun 2002 B1
6458109 Henley et al. Oct 2002 B1
6488643 Tumey et al. Dec 2002 B1
6520982 Boynton et al. Feb 2003 B1
6553998 Heaton et al. Apr 2003 B2
6557704 Randolph May 2003 B1
6599262 Masini Jul 2003 B1
6607495 Skalak et al. Aug 2003 B1
6626891 Ohmstede Sep 2003 B2
6648862 Watson Nov 2003 B2
6685681 Lockwood et al. Feb 2004 B2
6695823 Lina et al. Feb 2004 B1
6695824 Howard et al. Feb 2004 B2
6752794 Lockwood et al. Jun 2004 B2
6755807 Risk, Jr. et al. Jun 2004 B2
6764462 Risk, Jr. et al. Jul 2004 B2
6767334 Randolph Jul 2004 B1
6787682 Gilman Sep 2004 B2
6794554 Sessions et al. Sep 2004 B2
6800074 Henley et al. Oct 2004 B2
6814079 Heaton et al. Nov 2004 B2
6824533 Risk, Jr. et al. Nov 2004 B2
6855135 Lockwood et al. Feb 2005 B2
6855860 Ruszczak et al. Feb 2005 B2
6856821 Johnson Feb 2005 B2
6936037 Bubb et al. Aug 2005 B2
6942633 Odland Sep 2005 B2
6942634 Odland Sep 2005 B2
6951553 Bubb et al. Oct 2005 B2
6979324 Bybordi et al. Dec 2005 B2
7022113 Lockwood et al. Apr 2006 B2
7048951 Seitz et al. May 2006 B1
7067709 Murate et al. Jun 2006 B2
7077832 Fleischmann Jul 2006 B2
7087806 Scheinberg et al. Aug 2006 B2
7108683 Zamierowski Sep 2006 B2
7117869 Heaton et al. Oct 2006 B2
7128735 Weston Oct 2006 B2
7195624 Lockwood et al. Mar 2007 B2
7216651 Argenta et al. May 2007 B2
7230154 Sigurjonsson Jun 2007 B2
7361184 Joshi Apr 2008 B2
7381859 Hunt et al. Jun 2008 B2
7438705 Karpowicz et al. Oct 2008 B2
7524315 Blott et al. Apr 2009 B2
7532953 Vogel May 2009 B2
7534927 Lockwood et al. May 2009 B2
7553306 Hunt et al. Jun 2009 B1
7569742 Haggstrom et al. Aug 2009 B2
7605298 Bechert et al. Oct 2009 B2
7611500 Lina et al. Nov 2009 B1
7615036 Joshi et al. Nov 2009 B2
7622629 Aali Nov 2009 B2
7625362 Boehringer et al. Dec 2009 B2
7629384 Fossel Dec 2009 B2
7645253 Gura et al. Jan 2010 B2
7699823 Haggstrom et al. Apr 2010 B2
7700819 Ambrosio et al. Apr 2010 B2
7708724 Weston May 2010 B2
7718249 Russell et al. May 2010 B2
7722582 Lina et al. May 2010 B2
7723560 Lockwood et al. May 2010 B2
7749531 Booher Jul 2010 B2
7759537 Bishop et al. Jul 2010 B2
7759539 Shaw et al. Jul 2010 B2
7775998 Riesinger Aug 2010 B2
7776028 Miller et al. Aug 2010 B2
7779625 Joshi et al. Aug 2010 B2
7811269 Boynton et al. Oct 2010 B2
7815616 Boehringer et al. Oct 2010 B2
7837673 Vogel Nov 2010 B2
7838717 Haggstrom et al. Nov 2010 B2
7846141 Weston Dec 2010 B2
7896864 Lockwood et al. Mar 2011 B2
7909805 Weston Mar 2011 B2
7910791 Coffey Mar 2011 B2
7922676 Daskal et al. Apr 2011 B2
7922703 Riesinger Apr 2011 B2
7942866 Radl et al. May 2011 B2
7959624 Riesinger Jun 2011 B2
7964766 Blott et al. Jun 2011 B2
7976519 Bubb et al. Jul 2011 B2
8034037 Adams et al. Oct 2011 B2
8062272 Weston Nov 2011 B2
8062273 Weston Nov 2011 B2
8062331 Zamierowski Nov 2011 B2
8080702 Blott et al. Dec 2011 B2
8092441 Sugito Jan 2012 B2
8118794 Weston Feb 2012 B2
8152785 Vitaris Apr 2012 B2
8168848 Lockwood et al. May 2012 B2
8207392 Haggstrom et al. Jun 2012 B2
8212100 Moore Jul 2012 B2
8235972 Adahan Aug 2012 B2
8282611 Weston Oct 2012 B2
8303552 Weston Nov 2012 B2
8372049 Jaeb et al. Feb 2013 B2
8372050 Jaeb et al. Feb 2013 B2
8398614 Blott et al. Mar 2013 B2
8409157 Haggstrom et al. Apr 2013 B2
8444612 Patel et al. May 2013 B2
8460255 Joshi et al. Jun 2013 B2
8529548 Blott et al. Sep 2013 B2
8535283 Heaton et al. Sep 2013 B2
8535296 Blott et al. Sep 2013 B2
8545464 Weston Oct 2013 B2
8556871 Mormino et al. Oct 2013 B2
8569566 Blott et al. Oct 2013 B2
8628505 Weston Jan 2014 B2
8679079 Heaton et al. Mar 2014 B2
8795243 Weston Aug 2014 B2
8829263 Haggstrom et al. Sep 2014 B2
8834451 Blott et al. Sep 2014 B2
8864748 Coulthard et al. Oct 2014 B2
8915895 Jaeb et al. Dec 2014 B2
8956336 Haggstrom et al. Feb 2015 B2
9168330 Joshi et al. Oct 2015 B2
9198801 Weston Dec 2015 B2
9211365 Weston Dec 2015 B2
9302033 Riesinger Apr 2016 B2
9381283 Adams et al. Jul 2016 B2
9669138 Joshi et al. Jun 2017 B2
9795725 Joshi et al. Oct 2017 B2
10105471 Weston Oct 2018 B2
10265445 Weston Apr 2019 B2
10384041 Patel et al. Aug 2019 B2
10463773 Haggstrom et al. Nov 2019 B2
10765785 Quisenberry Sep 2020 B2
11691995 Schoenfisch et al. Jul 2023 B2
20010018072 Unger Aug 2001 A1
20010031943 Urie Oct 2001 A1
20010037810 Fine et al. Nov 2001 A1
20010043943 Coffey Nov 2001 A1
20020065494 Lockwood et al. May 2002 A1
20020115952 Johnson et al. Aug 2002 A1
20020143286 Tumey Oct 2002 A1
20020161346 Lockwood et al. Oct 2002 A1
20030040687 Boynton et al. Feb 2003 A1
20030045865 Knapp Mar 2003 A1
20030078532 Ruszczak et al. Apr 2003 A1
20030093041 Risk, Jr. et al. May 2003 A1
20030097100 Watson May 2003 A1
20030125646 Whitlock Jul 2003 A1
20030144619 Augustine Jul 2003 A1
20030212357 Pace Nov 2003 A1
20030212359 Butler Nov 2003 A1
20030219469 Johnson et al. Nov 2003 A1
20040006319 Lina Jan 2004 A1
20040039415 Zamierowski Feb 2004 A1
20040054338 Bybordi Mar 2004 A1
20040057855 Gerlach et al. Mar 2004 A1
20040064111 Lockwood et al. Apr 2004 A1
20040064132 Boehringer et al. Apr 2004 A1
20040073151 Weston Apr 2004 A1
20040076662 Riesinger Apr 2004 A1
20040087884 Haddock et al. May 2004 A1
20040093026 Weidenhagen et al. May 2004 A1
20040126413 Sigurjonsson et al. Jul 2004 A1
20040167482 Watson Aug 2004 A1
20040193218 Butler Sep 2004 A1
20040241213 Bray Dec 2004 A1
20040249353 Risk, Jr. et al. Dec 2004 A1
20040260230 Randolph Dec 2004 A1
20050004550 Sun Jan 2005 A1
20050012616 Forster et al. Jan 2005 A1
20050020955 Sanders et al. Jan 2005 A1
20050065471 Kuntz Mar 2005 A1
20050085795 Lockwood et al. Apr 2005 A1
20050090787 Risk et al. Apr 2005 A1
20050119737 Bene et al. Jun 2005 A1
20050131327 Lockwood et al. Jun 2005 A1
20050137539 Biggie et al. Jun 2005 A1
20050147562 Hunter et al. Jul 2005 A1
20050177093 Barry et al. Aug 2005 A1
20050251068 Mor Nov 2005 A1
20060009744 Erdman et al. Jan 2006 A1
20060029650 Coffey Feb 2006 A1
20060034816 Davis et al. Feb 2006 A1
20060107642 Smith et al. May 2006 A1
20060213527 Argenta et al. Sep 2006 A1
20060259102 Slatkine Nov 2006 A1
20070040454 Freudenberger et al. Feb 2007 A1
20070055209 Patel et al. Mar 2007 A1
20070066945 Martin Mar 2007 A1
20070078366 Haggstrom et al. Apr 2007 A1
20070128055 Lee Jun 2007 A1
20070179460 Adahan Aug 2007 A1
20070219512 Heaton et al. Sep 2007 A1
20070225663 Watt et al. Sep 2007 A1
20070255187 Branch Nov 2007 A1
20070255194 Gudnason et al. Nov 2007 A1
20070265586 Joshi et al. Nov 2007 A1
20080031748 Ihle et al. Feb 2008 A1
20080051716 Stutz Feb 2008 A1
20080108977 Heaton et al. May 2008 A1
20080132821 Propp et al. Jun 2008 A1
20080200905 Heaton et al. Aug 2008 A1
20080306456 Riesinger Dec 2008 A1
20090012484 Nielsen et al. Jan 2009 A1
20090069759 Blott et al. Mar 2009 A1
20090124988 Coulthard May 2009 A1
20090137973 Karpowicz et al. May 2009 A1
20090192431 Horstmann et al. Jul 2009 A1
20090204085 Biggie et al. Aug 2009 A1
20090214624 Smith et al. Aug 2009 A1
20090275922 Coulthard et al. Nov 2009 A1
20110118683 Weston May 2011 A1
20110295220 Heaton et al. Dec 2011 A1
20120041399 Blott et al. Feb 2012 A1
20130090615 Jaeb et al. Apr 2013 A1
20130102979 Coulthard et al. Apr 2013 A1
20130116635 Fleischmann May 2013 A1
20130138054 Fleischmann May 2013 A1
20130150814 Buan Jun 2013 A1
20130331822 Patel Dec 2013 A1
20130338614 Heaton et al. Dec 2013 A1
20140100539 Coulthard et al. Apr 2014 A1
20140155849 Heaton et al. Jun 2014 A1
20140188061 Locke et al. Jul 2014 A1
20140200535 Locke et al. Jul 2014 A1
20140276490 Locke et al. Sep 2014 A1
20140276491 Luckemeyer et al. Sep 2014 A1
20140276497 Robinson Sep 2014 A1
20140309601 Hall et al. Oct 2014 A1
20140343519 Weston Nov 2014 A1
20150065965 Haggstrom Mar 2015 A1
20150080787 Blott et al. Mar 2015 A1
20150119829 Haggstron et al. Apr 2015 A1
20150165101 Blott et al. Jun 2015 A1
20150173954 Blott et al. Jun 2015 A1
20150209492 Blott et al. Jul 2015 A1
20180028729 Joshi et al. Feb 2018 A1
Foreign Referenced Citations (63)
Number Date Country
34 43 101 May 1986 DE
198 44 355 Apr 2000 DE
20 2004 017 052 Jun 2005 DE
202004018245 Aug 2005 DE
0 340 018 Nov 1989 EP
0 512 543 Nov 1992 EP
0 853 950 Jul 1998 EP
1076586 Feb 2001 EP
1 088 569 Apr 2001 EP
1 219 311 Jul 2002 EP
1 476 217 Mar 2008 EP
1 955 887 Aug 2008 EP
2 462 908 Jun 2012 EP
2 603 699 Jun 2013 EP
2 079 507 Jan 2014 EP
2 687 245 Jan 2014 EP
2 711 034 Mar 2014 EP
2 305 325 Apr 2014 EP
2 345 437 Apr 2014 EP
3 072 542 Sep 2016 EP
3167916 May 2017 EP
3 062 751 Aug 2017 EP
3 257 486 Dec 2017 EP
1 163 907 Oct 1958 FR
2 939 320 Jun 2010 FR
1255395 Dec 1971 GB
2307180 May 1997 GB
2329127 Mar 1999 GB
2336546 Oct 1999 GB
2344531 Jun 2000 GB
2511523 Sep 2014 GB
H04-354722 Dec 1992 JP
131622 Aug 2013 RU
WO 198300742 Mar 1983 WO
WO-9216245 Oct 1992 WO
WO 1993009727 May 1993 WO
WO 1994020041 Sep 1994 WO
WO 199605873 Feb 1996 WO
WO 200021586 Apr 2000 WO
WO 2003005943 Jan 2003 WO
WO 2003018098 Mar 2003 WO
WO 2003030966 Apr 2003 WO
WO 2003045492 Jun 2003 WO
WO 2003057070 Jul 2003 WO
WO 2003057071 Jul 2003 WO
WO 2003057307 Jul 2003 WO
WO 2003086232 Oct 2003 WO
WO 2003092620 Nov 2003 WO
WO 2003101508 Dec 2003 WO
WO 2004018020 Mar 2004 WO
WO 2004077387 Sep 2004 WO
WO 2005009488 Feb 2005 WO
WO-2005046760 May 2005 WO
WO-2005105180 Nov 2005 WO
WO 2005123170 Dec 2005 WO
WO 2006052839 May 2006 WO
WO-2006095193 Sep 2006 WO
WO-2007084533 Jul 2007 WO
WO-2007084599 Jul 2007 WO
WO-2007113597 Oct 2007 WO
WO 2014113504 Jul 2014 WO
WO 2014107285 Sep 2014 WO
WO 2014143488 Sep 2014 WO
Non-Patent Literature Citations (11)
Entry
International Search Report and Written Opinion, re PCT Application No. PCT/US2006/034824, dated Mar. 20, 2007.
International Preliminary Report on Patentability, re PCT Application No. PCT/US2006/034824, dated Mar. 11, 2008.
International Search Report and Written Opinion, re PCT Application No. PCT/EP2016/059329, dated Jul. 14, 2016.
Kendall ULTEC Hydrocolloid Dressing (4″x4″), product ordering page, web page downloaded Jul. 13, 2014, in 1 page.
Advantec MFS, Inc., “Membrane Filters” (catalog), accessed Jan. 29, 2016 (publication date unknown, but believed to be copyright 2001-2011), in 17 pages. URL: http://www.advantecmfs.com/catalog/filt/membrane.pdf#page=11.
Nullification of the German part of European patent 2 021 046 (German file references 60 2007 021 330.4), dated Nov. 23, 2015, with translation.
Pentair Pool Products, 2000 Series Stainless Steel D. E. Filters (2006), in 2 pages.
Protz, K., “Moderne Wundauflagen unterstutzen Heilungsprozess”, Wundversorgung: Indikation und Anwendung, Geriatrie Journal, Apr. 2005, pp. 3333-3339, with translation, in 17 pages.
“Technology Watch”, May 1989, in 1 page.
Hersle, K. et al., “Uses of Dextranomer Absorbent Pads After Cryosurgery of Cutaneous Malignancies”, The Journal of Dermatologic Surgery and Oncology, vol. 8, Jan. 1982, in 4 pages.
Smith & Nephew, “PICO Single Use Negative Pressure Wound Therapy System”, spiral booklet, Mar. 2011, in 7 pages.
Related Publications (1)
Number Date Country
20200139023 A1 May 2020 US
Provisional Applications (1)
Number Date Country
60714805 Sep 2005 US
Divisions (1)
Number Date Country
Parent 11516925 Sep 2006 US
Child 12686813 US
Continuations (4)
Number Date Country
Parent 15280009 Sep 2016 US
Child 16668589 US
Parent 14585589 Dec 2014 US
Child 15280009 US
Parent 13775964 Feb 2013 US
Child 14585589 US
Parent 12686813 Jan 2010 US
Child 13775964 US